Jump to content

Philip Lazarovici

Add links
From Wikipedia, the free encyclopedia

Philip Lazarovici is a neuropharmacologist at the Hebrew University of Jerusalem and a member of the Institute of Drug Research of the School of Pharmacy.[1]

Education

[edit]

Philip was born to Bracha (Fishler) and Leon Lazarovici on 1 October 1949 in Roman, Romania to a Jewish family. When he was 13 years old, his family immigrated to Israel where he developed an early interest in biology. He attended the Alliance Israélite Universelle-Carmia High School in Jerusalem and later, he enrolled in Israeli Defense Forces (IDF) Armored Infantry until 1971, serving as first sergeant. He completed his Bachelor of Science in biology, Master of Sciences in zoology, and Doctor of Philosophy (PhD) in toxicology, all from The Hebrew University of Jerusalem, Israel. He began his postdoctoral fellowship in Neurobiology at The Weizmann Institute of Science, Rehovot, Israel.[2]

Research and career

[edit]

Lazarovici mainly researched on a variety of cellular and molecular aspects in the fields of neuroscience and cancer with a major emphasis on nerve growth factor (NGF) and toxins action, to dissect and characterize different biological aspects and to provide lead compounds for drug development.[3] He along with his NIH colleagues, has contributed to the consensus-signaling map of NGF in neuronal differentiation, which has been recognized by the Signal Transduction Knowledge Environment (STKE).[4]

He developed and investigated different neuroprotective compounds and approaches towards neuronal ischemia in stroke, and traumatic brain injury. Lazarovici also contributed to the characterization of NGF angiogenic properties and characterization of human umbilical cord blood-derived stem cells.[5][6] He is best known for his work on heterologous down-regulation of EGF receptor by NGF, which would appear to be an efficient mean of desensitizing the neurons to proliferative signals.[7][8][9][10]

Lazarovici pursued neuroscience as a visiting associate in the Section on Growth Factors at National Institute of Child Health and Human Development, NIH, Bethesda, MD, USA. After completion of his research, he joined as lecturer in The School of Pharmacy, The Hebrew University of Jerusalem and later he became the full Professor. He is an active member of the Israel Societies for Physiology and Pharmacology (ISPP), and Neuroscience (ISN), American Societies for Neuroscience (ASN), and Pharmacology and Experimental Therapeutics (ASPET). Lazarovici was part of the Israeli group developing with TEVA Co. the drug for Parkinson's named Rasagiline (Azilect).[11] Lazarovici is one of the highly cited author with a h-index of 49, he published around 235 scientific articles and edited six books in his field of research.[12]

Patents

[edit]

Lazarovici, together with his collaborators, obtained many patents for his inventions. His patents include; "Three-dimensional scaffolds for tissue engineering made by processing complex extracts of natural extracellular matrices"; "Near-infrared fluorescent particles and uses thereof"; "Soy-derived bioactive peptides for use in compositions and methods for wound healing, tissue engineering, and regenerative medicine"; and "Viperistatin-derived peptides and uses thereof".[13][14][15][16]

Publications

[edit]
  • Vaudry, D.; Stork, PJ; Lazarovici, P; Eiden, LE (31 May 2002). "Signaling Pathways for PC12 Cell Differentiation: Making the Right Connections". Science. 296 (5573): 1648–1649. Bibcode:2002Sci...296.1648V. doi:10.1126/science.1071552. PMID 12040181. S2CID 24865425.
  • Tabakman, R.; Jiang, H; Shahar, I; Arien-Zakay, H; Levine, RA; Lazarovici, P (1 August 2005). "Neuroprotection by NGF in the PC12 In Vitro OGD Model: Involvement of Mitogen-Activated Protein Kinases and Gene Expression". Annals of the New York Academy of Sciences. 1053 (1): 84–96. Bibcode:2005NYASA1053...84T. doi:10.1196/annals.1344.008. PMID 16179511.
  • Lahiani, Adi; Brand-Yavin, Annette; Yavin, Ephraim; Lazarovici, Philip (8 February 2018). "Neuroprotective Effects of Bioactive Compounds and MAPK Pathway Modulation in "Ischemia"—Stressed PC12 Pheochromocytoma Cells". Brain Sciences. 8 (2): 32. doi:10.3390/brainsci8020032. PMC 5836051. PMID 29419806.
  • Gincberg, Galit; Shohami, Esther; Trembovler, Victoria; Alexandrovich, Alexander G.; Lazarovici, Philip; Elchalal, Uriel (February 2018). "Nerve growth factor plays a role in the neurotherapeutic effect of a CD45 + pan-hematopoietic subpopulation derived from human umbilical cord blood in a traumatic brain injury model". Cytotherapy. 20 (2): 245–261. doi:10.1016/j.jcyt.2017.11.008. PMID 29274773.
  • Karatzas, Andreas; Katsanos, Konstantinos; Lilis, Ioannis; Papadaki, Helen; Kitrou, Panagiotis; Lecht, Shimon; Marcinkiewicz, Cezary; Siablis, Dimitris; Lelkes, Peter I.; Lazarovici, Philip; Tsopanoglou, Nikos E. (September 2013). "NGF Promotes Hemodynamic Recovery in a Rabbit Hindlimb Ischemic Model Through trkA- and VEGFR2-dependent Pathways". Journal of Cardiovascular Pharmacology. 62 (3): 270–277. doi:10.1097/FJC.0b013e3182982de7. PMID 23644989. S2CID 601556.
  • Mirshahi, P; Rafii, A; Vincent, L; Berthaut, A; Varin, R; Kalantar, G; Marzac, C; Calandini, O A; Marie, J-P; Soria, C; Soria, J; Mirshahi, M (2 April 2009). "Vasculogenic mimicry of acute leukemic bone marrow stromal cells". Leukemia. 23 (6): 1039–1048. doi:10.1038/leu.2009.10. PMID 19340002.
  • Cohen, Gadi; Ettinger, Keren; Lecht, Shimon; Lelkes, Peter I.; Lazarovici, Philip (31 July 2014). "Transcriptional Down-regulation of Epidermal Growth Factor (EGF) Receptors by Nerve Growth Factor (NGF) in PC12 Cells". Journal of Molecular Neuroscience. 54 (3): 574–585. doi:10.1007/s12031-014-0388-2. PMID 25078264. S2CID 1620005.

References

[edit]
  1. ^ "Professor Philip Lazarovici". medicine.ekmd.huji.ac.il. Retrieved 2020-05-13.
  2. ^ "NobleResearch". nobleresearch.org. Retrieved 2020-05-13.
  3. ^ Strande, Jennifer L.; Routhu, Kasi V.; Lecht, Shimon; Lazarovici, Philip (1 January 2013). "Nerve growth factor reduces myocardial ischemia/reperfusion injury in rat hearts". Journal of Basic and Clinical Physiology and Pharmacology. 24 (1): 81–4. doi:10.1515/jbcpp-2012-0045. PMC 3938895. PMID 23314533.
  4. ^ Vaudry, D.; Stork, PJ; Lazarovici, P; Eiden, LE (31 May 2002). "Signaling Pathways for PC12 Cell Differentiation: Making the Right Connections". Science. 296 (5573): 1648–1649. Bibcode:2002Sci...296.1648V. doi:10.1126/science.1071552. PMID 12040181. S2CID 24865425.
  5. ^ Lazarovici, Philip; Gazit, Aviv; Staniszewska, Izabela; Marcinkiewicz, Cezary; Lelkes, Peter I. (13 July 2009). "Nerve Growth Factor (NGF) Promotes Angiogenesis in the Quail Chorioallantoic Membrane". Endothelium. 13 (1): 51–59. doi:10.1080/10623320600669053. PMID 16885067.
  6. ^ Lazarovici, Philip; Lahiani, Adi; Gincberg, Galit; Haham, Dikla; Fluksman, Arnon; Benny, Ofra; Marcinkiewicz, Cezary; Lelkes, Peter I. (2018). "Nerve Growth Factor-Induced Angiogenesis: 1. Endothelial Cell Tube Formation Assay". Neurotrophic Factors. Methods in Molecular Biology. Vol. 1727. pp. 239–250. doi:10.1007/978-1-4939-7571-6_18. ISBN 978-1-4939-7570-9. PMID 29222786.
  7. ^ "Israeli embassy". embassies.gov.il. Retrieved 2020-05-13.
  8. ^ Lazarovici, Philip; Oshima, Mari; Shavit, Davidit; Shibutani, Makoto; Jiang, Hao; Monshipouri, Mariam; Fink, Donald; Movsesyan, Vilen; Guroff, Gordon (25 April 1997). "Down-regulation of Epidermal Growth Factor Receptors by Nerve Growth Factor in PC12 Cells Is p140trk-, Ras-, and Src-dependent". Journal of Biological Chemistry. 272 (17): 11026–11034. doi:10.1074/jbc.272.17.11026. PMID 9110995.
  9. ^ Cohen, Gadi; Ettinger, Keren; Lecht, Shimon; Lelkes, Peter I.; Lazarovici, Philip (31 July 2014). "Transcriptional Down-regulation of Epidermal Growth Factor (EGF) Receptors by Nerve Growth Factor (NGF) in PC12 Cells". Journal of Molecular Neuroscience. 54 (3): 574–585. doi:10.1007/s12031-014-0388-2. PMID 25078264. S2CID 1620005.
  10. ^ Lazarovici, Philip; Fink, Donald (August 1999). "Heterologous Upregulation of Nerve Growth Factor-TrkA Receptors in PC12 Cells by Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP)". Molecular Cell Biology Research Communications. 2 (2): 97–102. doi:10.1006/mcbr.1999.0158. PMID 10542132.
  11. ^ Lecht, Shimon; Haroutiunian, Simon; Hoffman, Amnon; Lazarovici, Philip (2007). "Rasagiline – a novel MAO B inhibitor in Parkinson's disease therapy". Therapeutics and Clinical Risk Management. 3 (3): 467–474. PMC 2386362. PMID 18488080.
  12. ^ "Philip Lazarovici - Google Scholar Citations". scholar.google.com. Retrieved 2020-05-13.
  13. ^ US 9725693, Lelkes, Peter I.; Li, Mengyan & Perets, Anat et al., "Three-dimensional scaffolds for tissue engineering made by processing complex extracts of natural extracellular matrices", published 2017-08-08, assigned to Drexel University 
  14. ^ WO 2012032524, Magdassi, Shlomo; Lazarovici, Philip & Larush, Liraz et al., "Near infrared fluorescent particles and uses thereof", published 2012-03-150, assigned to Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. and inventors 
  15. ^ EP 3325029, Lelkes, Peter I.; Har-El, Yah-el H. & Marcinkiewicz, Cezary et al., "Soy-derived bioactive peptides for use in compositions and methods for wound healing, tissue engineering, and regenerative medicine", published 2018-05-30, assigned to Temple University 
  16. ^ WO 2015087334, Lazarovici, Philip; Momic, Tatjana & Marcinkiewicz, Cezary et al., "Viperistatin-derived peptides and uses thereof", issued 2014-12-14, assigned to Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. and Temple University 
Retrieved from "https://en.wikipedia.org/w/index.php?title=Philip_Lazarovici&oldid=1238501661"